ArticleAnnals of hematology2024

Prognostic impact of 1q abnormality on outcomes in patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide and dexamethasone in a real-world clinical setting.

Taku Kikuchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.